Bristol-Myers Squibb Company (BMY) Presents at Jefferies Healthcare Conference (Transcript)Seeking Alpha • 06/08/23
Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023Business Wire • 06/08/23
Bristol-Myers Squibb Company (BMY) Presents at 2023 Virtual ASCO Investor Event Conference (Transcript)Seeking Alpha • 06/06/23
MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target DiscoveryBusiness Wire • 06/05/23
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung CancerBusiness Wire • 06/04/23
High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good BetSeeking Alpha • 05/30/23
Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant LymphomaBusiness Wire • 05/30/23
Bristol_Myers says FDA has accepted its non-small lung cancer treatment repotrectinib for priority reviewMarket Watch • 05/30/23
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerBusiness Wire • 05/30/23
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 ExpreBusiness Wire • 05/26/23
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023Business Wire • 05/25/23
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)Business Wire • 05/25/23
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial FibrillationBusiness Wire • 05/25/23
Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary FibrosisBusiness Wire • 05/22/23